WO2026119170 - USE OF FGF21/GLP-1 FUSION PROTEIN
National phase entry is expected:
Publication Number
WO/2026/119170
Publication Date
11.06.2026
International Application No.
PCT/CN2025/139568
International Filing Date
03.12.2025
Title **
[English]
USE OF FGF21/GLP-1 FUSION PROTEIN
[French]
UTILISATION D'UNE PROTÉINE DE FUSION FGF21/GLP-1
[Chinese]
FGF21/GLP-1融合蛋白的用途
Applicants **
SUNSHINE LAKE PHARMA CO., LTD.
Inventors
XIE, Can
YAN, Jiangyu
GUO, Linfeng
Priority Data
202411772494.5
04.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1591 | |
| EPO | Filing, Examination, Granting | 11726 | |
| Japan | Filing, Examination, Granting | 2018 | |
| South Korea | Filing, Examination, Granting | 1788 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,463
Contact Us
Abstract[English]
Provided is use of an FGF21/GLP-1 fusion protein in the preparation of a drug for preventing and/or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21/GLP-1 fusion protein can effectively treat at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. Especially, the fusion protein can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in a subject, or can improve at least one of adiponectin, insulin sensitivity, and β cell function in the subject.[French]
L'invention concerne l'utilisation d'une protéine de fusion FGF21/GLP-1 dans la préparation d'un médicament pour la prévention et/ou le traitement d'au moins une affection parmi le diabète de type 2, l'obésité, la stéatohépatite et la triglycéridémie. La protéine de fusion FGF21/GLP-1 peut traiter efficacement au moins une affection parmi le diabète de type 2, l'obésité, la stéatohépatite et la triglycéridémie. En particulier, la protéine de fusion peut réduire au moins un facteur parmi HbA1c, la glycémie, le poids corporel, la teneur en graisse hépatique, ALT, AST, la glutamyl-transpeptidase, les triglycérides, le cholestérol total et le cholestérol des lipoprotéines de faible densité chez un sujet, ou peut améliorer au moins un facteur parmi l'adiponectine, l'insulinosensibilité et la fonction des cellules bêta chez le sujet.[Chinese]
提供了FGF21/GLP-1融合蛋白在制备药物中的用途，所述药物用于预防和/或治疗2型糖尿病、肥胖、脂肪性肝炎、甘油三脂血症中至少之一。FGF21/GLP-1融合蛋白可有效治疗2型糖尿病、肥胖、脂肪性肝炎、甘油三脂血症中至少之一，尤其是可降低施用者的HbA1c、血糖、体重、肝脂肪含量、ALT、AST、谷氨酰基转肽酶、甘油三酯、总胆固醇、低密度脂蛋白胆固醇中的至少之一，或者提高施用者的脂联素、胰岛素敏感性、β细胞功能中的至少之一。